Immusoft to Present at ASGCT 23rd Annual Meeting

- Two presentations to highlight the transposon-engineered B lymphocytes ISP™ platform for MPS I and enhancement of muscle mass –

SEATTLE--()--Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced two upcoming virtual oral presentations at the ASGCT 23rd Annual Meeting Virtual Format, hosted from May 12 – 15, 2020. Registration for the meeting can be accessed at https://www.mylibralounge.com/sites/asgct2020/attendee/.

Dr. Glen Grandea will present, “Follistatin Overexpression in Sleeping Beauty-Transposed, In Vitro Differentiated Human Plasmablasts: Enhancement of Muscle Mass and Strength in NSG Mice after Adoptive Transfer” at 5:00 p.m. ET / 2:00 p.m. PT on Thursday, May 14, 2020 during the Muscolo-skeletal Diseases II session.

On Friday, May 15, 2020, Dr. Chistiane Hampe will present, “Sleeping Beauty IDUA Transposed Human Plasma Cells for Long-Term Treatment of an Immunodeficient Murine Model of Mucopolysaccharidosis Type I” at 10:30 a.m. ET / 7:30 a.m. PT during the Technical Advances in Cell Therapies Session.

Additional information regarding the ISP™ platform can be found at: https://immusoft.com/technology/

For more information regarding ASGCT please visit: https://www.asgct.org/am20.

“We are excited to have been selected to give two presentations this year at ASGCT.” Stated Sean Ainsworth, CEO. “The powerful data in two disparate therapeutic areas speaks clearly to the value of our platform as a modality for improved delivery of protein therapeutics in a cell therapy approach.”

About Immune System Programming (ISP™) Technology

Immusoft’s proprietary ISP™ platform technology is a gene modified cell therapy approach that uses a clinically validated, non-viral vector that aims to safely and reliably insert functional genes into immune cells. Once administered back into the patient, a subset of ISP™ modified cells are expected to reside within survival niches in the body, continuously producing gene-encoded protein(s). The platform’s broad utility to produce a wide range of therapeutic protein classes (e.g. antibodies, signaling proteins, and enzymes), has the potential to disrupt the current standard of care for many diseases requiring protein injections or infusions, including many to address orphan diseases.

About Mucopolysaccharidosis type I (MPS I)

MPS I is a rare, lethal childhood genetic disease that affects the body’s ability to produce IDUA (alpha-L-iduronidase), which is an essential enzyme that helps to break down long-chain sugars inside cells. When the sugar chains cannot be broken down and disposed of, they accumulate in the cells and cause progressive damage. In its most severe form, and if left untreated, children affected rarely live longer than ten years after diagnosis.

About Follistatin for Muscle and Strength Enhancement

Follistatin is a naturally occurring protein in the body, which is involved in increasing muscle mass. One way in which it does so is by inhibiting a protein, Myostatin, whose function is to keep muscle growth in check. Follistatin also has Myostatin-independent activity, which promotes muscle growth and increased strength. Immusoft is investigating follistatin as a potential therapeutic for muscle wasting conditions such as muscular dystrophy and ALS.

About Immusoft

Immusoft Corporation’s (immusoft.com) mission is to treat diseases using its breakthrough technology platform called Immune System Programming (ISP™). The technology modifies a patient’s B cells and instructs the cells to produce gene-encoded medicines (biologics). The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. Immusoft Corporation is based in Seattle, Washington.

Contacts

Media & Investors
Glenn Schulman, PharmD, MPH
Z3 Biocommunications, LLC
email glenn@z3bio.com
tel (203)494-7411

Contacts

Media & Investors
Glenn Schulman, PharmD, MPH
Z3 Biocommunications, LLC
email glenn@z3bio.com
tel (203)494-7411